Try our Advanced Search for more refined results
Solis v. Millennium Pharmaceuticals, Inc. et al
Case Number:
2:09-cv-03010
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 02, 2020
Merck, Takeda Unit Beat Off-Label FCA Kickbacks Suit
A California federal judge tossed a whistleblower's allegations that Merck and Co. and two other drugmakers violated the False Claims Act by offering doctors kickbacks to prescribe their blood-thinning drugs, saying the former sales employee didn't have direct knowledge of the alleged fraud.
-
September 01, 2015
Merck Beats Back Whistleblower's FCA Claims Over Integrilin
A California federal judge on Monday tossed a whistleblower's False Claims Act allegations against Merck and Co. Inc. of off-label promotion of Integrilin and kickbacks, ruling they were substantially similar to claims against Millennium Pharmaceuticals Inc. that he had previously dismissed.
-
April 03, 2015
Merck Wants FCA Claim Tossed After Millennium Escapes Suit
Merck and Co. Inc. on Friday asked a California federal judge to dismiss a whistleblower's False Claims Act allegations regarding off-label promotion of Integrilin and kickbacks, saying the judge's grounds for dismissing similar claims against Millennium Pharmaceuticals Inc. were equally applicable to it.
-
March 26, 2015
Millennium Beats Off-Label Suit, But Free Speech No Factor
A California federal judge on Thursday threw out a False Claims Act suit accusing Millennium Pharmaceuticals Inc. of illicit off-label promotion, but the ruling omitted any discussion of free-speech issues in the closely watched whistleblower case.
-
September 19, 2014
FCA Free Speech Defense Tested In DOJ-PhRMA Fight
A fiery feud in California federal court between the U.S. Department of Justice and Pharmaceutical Research and Manufacturers of America shows the gloves are finally off in a fight that will shape the future of False Claims Act litigation, experts say, with opposing sides clashing over whether the First Amendment always shields honest off-label promotion.
-
September 09, 2014
PhRMA Fires Back At Feds In FCA Off-Label Suit
Pharmaceutical Research and Manufacturers of America on Tuesday escalated a high-stakes war of words with the U.S. Department of Justice in a whistleblower's False Claims Act suit in California federal court involving off-label promotion, accusing government attorneys of advancing a theory of liability with "no rational stopping point."
-
August 29, 2014
Feds Rip PhRMA's Free Speech Claims In FCA Off-Label Suit
The U.S. Department of Justice is urging a California federal judge to reject free speech arguments advanced in a False Claims Act case by Pharmaceutical Research and Manufacturers of America, adding more fuel to a fiery debate surrounding punishment of off-label promotion.
-
August 18, 2014
PhRMA Says Integrilin FCA Suit Stifles Free Speech Rights
The Pharmaceutical Research and Manufacturers of America on Friday urged a California federal court to dismiss a whistleblower's False Claims Act suit accusing two drugmakers of misbranding heart medication Integrilin and of paying kickbacks to doctors, saying the off-label claims in the case stepped on the companies' free speech rights.
-
May 31, 2013
Schering Says FCA Integrilin Kickbacks Suit Doesn't Stick
Schering-Plough Corp. and Millennium Pharmaceuticals Inc. asked a California federal judge Thursday to dismiss a whistleblower's False Claims Act suit accusing them of misbranding heart medication Integrilin and paying kickbacks to doctors, saying the plaintiff failed show any actual false claims.
-
December 21, 2012
Judge Unseals FCA Suit Against Millennium, Schering
A California federal judge on Thursday unsealed a whistleblower's False Claims Act suit accusing Millennium Pharmaceuticals Inc. and Schering-Plough Corp. of illegally marketing heart medication for unapproved off-label uses, saying the U.S. government had declined to intervene in the case.